Enfusion Inc [ENFN] stock prices are up 8.75% to $10.81 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ENFN shares have gain 7.35% over the last week, with a monthly amount glided 2.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman downgraded its rating to Sell on February 28, 2024, and dropped its price target to $8. On January 30, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $9 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $9 on November 07, 2023. Piper Sandler initiated its recommendation with a Neutral and recommended $11 as its price target on April 03, 2023. JP Morgan started tracking with a Neutral rating for this stock on March 15, 2023, and assigned it a price target of $12. In a note dated January 04, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $15 to $10.
The stock price of Enfusion Inc [ENFN] has been fluctuating between $7.52 and $11.38 over the past year. Enfusion Inc [NYSE: ENFN] shares were valued at $10.81 at the most recent close of the market.
Analyzing the ENFN fundamentals
The Enfusion Inc [NYSE:ENFN] reported sales of 195.16M for trailing twelve months, representing a surge of 15.35%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.40 points at the first support level, and at 10.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.06, and for the 2nd resistance point, it is at 11.31.
Ratios To Look Out For
It’s worth pointing out that Enfusion Inc [NYSE:ENFN]’s Current Ratio is 3.62. As well, the Quick Ratio is 3.62, while the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 7.12, the price to book ratio is 14.42 and price to earnings (TTM) ratio is 412.60.
Transactions by insiders
Recent insider trading involved Somers Deirdre, Director, that happened on Jan 13 ’25 when 1637.0 shares were purchased. Chief Executive Officer, Movchan Oleg completed a deal on Jan 07 ’25 to sell 2771.0 shares. Meanwhile, Chief Financial Officer Herring Bradley sold 4134.0 shares on Jan 07 ’25.
